MOBIMOBIA MEDICAL, INC.
Is Mobia Medical struggling financially?
Yes, by its own account. Mobia Medical told the SEC on 4 Jun 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed Jun 2026
30/100
Fragile
- Sector
- Biotech/Pharma
- Market cap
- $353.2M
- Source filing
- 10-Q 4 Jun 2026
- Balance sheet
- 30 Jun 2026
Cash runway
Not estimable
The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.
What it reported
Cash and short-term investments
$177.1M
What Mobia Medical told the SEC
…for the periods ended December 31, 2024 and 2025 included in the prospectus), the Company had previously concluded that the aforementioned factors raised substantial doubt about its ability to continue as a going concern. In May 2026, the Company completed its IPO and received net proceeds of approximately $ 134.5 million. As a result, the Company’s cash on hand, together with the net proceeds received…
MOBIA MEDICAL, INC., Form 10-Q, filed 4 Jun 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 1108.1% share-count increase The company issued stock. Each share now owns 91.7% less of the business than a year ago, before any change in the price.
Other Biotech/Pharma companies that filed the doubt
- LABT Lakewood-Amedex Biotherapeutics $5.3M
- MCRB Seres Therapeutics $45.8M
- MLSS Milestone Scientific $42.7M
- PIII P3 Health Partners $74.9M
- PLYX Polaryx Therapeutics $103.2M
- SCLX Scilex Holding Company $48.7M